Cochlear Shares Plummet as Next-Gen Implant Delays Hit Profitability
Sydney-based global hearing implant giant Cochlear has become the latest high-profile company to face a significant market reaction, experiencing a sharp drop in its share price after failing to meet profit forecasts. The company’s stock took a substantial hit, plunging 18.9 per cent to a three-year low of $199.22 on Friday. This downturn followed an announcement that the rollout of its next-generation implant, the Nucleus Nexa, had encountered unexpected delays, impacting the company’s financial outlook.
The interim statutory net profit for the six months ending December 31 revealed a 21 per cent decline, settling at $161.5 million. This was accompanied by a two per cent decrease in sales, bringing the total to $1.18 billion.
The delay in the launch of the much-anticipated Nucleus Nexa implant for the 2025 financial year has been attributed to challenges with product registration and contract renewals. Consequently, Cochlear has revised its full-year profit expectations downwards, anticipating it will now fall at the lower end of its previously issued guidance range of $435 million to $460 million.
Despite these rollout setbacks, Cochlear has indicated that the Nucleus Nexa is now available in most key markets and has been met with positive feedback from both healthcare professionals and implant recipients. The company highlighted the Nexa sound processor as a standout innovation, boasting the title of the world’s lightest and smallest. Furthermore, the implant itself is unique in its provision of upgradeable firmware, a feature designed to offer recipients long-term access to future technological advancements.
“Overall, we saw a very successful launch, which sets us up for the future,” stated Chief Executive and President Dig Howitt during a call with analysts on Friday. He also shared that Cochlear had largely been successful in negotiating favourable price increases for the new system with hospitals.
In terms of shareholder returns, Cochlear announced an interim dividend of $2.15 per share, maintaining the same payout level as the previous year. The dividend will be 85 per cent franked, an increase from the 80 per cent franking offered a year ago.
Market Volatility Grips Earnings Season
The market’s sharp reaction to Cochlear’s announcement underscores a broader trend of increased volatility during the current earnings season. Analysts at RBC Capital Markets noted that the financial results were below consensus expectations and their own forecasts. “We expect the stock to be weaker today given the soft 1H performance and management lowering full-year expectations,” commented analyst Craig Wong-Pan prior to the significant sell-off.
Cochlear is not an isolated case. Several other prominent Australian companies have experienced significant share price fluctuations around their earnings reports. Blue-chip biopharmaceutical company CSL, for instance, saw its shares decline by 15.6 per cent week-on-week by Friday. Wealth manager AMP and online furniture retailer Temple & Webster also faced substantial sell-offs, with AMP shares dropping by more than a quarter and Temple & Webster by almost a third on Thursday.
On the other hand, some companies have delivered strong results, buoying investor confidence. ANZ and Commonwealth Bank both reported robust gains with their earnings announcements. CBA’s shares climbed 6.8 per cent on Wednesday, marking its best performance since March 2020, while ANZ experienced a significant surge of 8.5 per cent on Thursday.
Reporting Season Becomes a Period of Heightened Uncertainty
Andrew Dale, a partner at Sydney-based ECP Asset Management, observed that the preceding week had also been characterised by considerable market movement. He suggested that international market trends, particularly questions surrounding the impact of artificial intelligence on the business models of expensive software-as-a-service companies, had contributed to this.
However, Mr Dale emphasised that the sharp share price movements are becoming increasingly pronounced during reporting seasons – the periods in February and August when most companies release their financial results. “It has become somewhat of a common trend that reporting season is a period of high volatility,” he remarked. “This shouldn’t be a surprise to investors, and should be expected going forward.” This heightened uncertainty means investors need to be prepared for significant swings in company valuations as financial performance is revealed.
